Valuation
26% of the score
21median 53
West Pharmaceutical Services is valued at 40.2x its operating profit, including debt: a very rich multiple.
60x
50x
35x
25x
18x
12x
8x
40.2x
Full points at 8x or less, none from 60xfull points
WSTWest Pharmaceutical Services
$392.07+47% 1Y
$392.07
$230.7852 weeks$394.16
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 59 out of 100, Average
Today's price. Only valuation depends on it.
Average. West Pharmaceutical Services scores higher than 57% of the 2,231 companies Ryufin scores.
Carried by return on capital and capital allocation, held back by valuation and return on new capital.
Healthcare median 19 · all companies 55
How the score has moved
At each fiscal year end, from the reports and price of the time57
57
71
67
68
63
59
202020212022202320242025today
The biggest move was up 14 points from 2021 to 2022, mostly valuation.
Return on capital
18% of the score
95median 24
Over 7 years the business earned 23% a year after tax on the capital it uses.
2%
8%
15%
25%
23%
None at 2% or less, full points from 25%full points
7 years agolatest 17%
Return on new capital
16% of the score
25median 33
Over 6 years yearly profit fell by 1 cents for every dollar earned. New capital earned -2.6%, and 32% of profit went back into the business.
-5%
12%
-0.8%
None at minus 5 cents, full points from 12 centsfull points
Capital allocation
14% of the score
74median 63
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countDown 0.8% a year over 5 years: buybacks
735%
-3%
-0.8%
0 pointsfull points
Assets against salesAssets grew 8.8% a year, sales 7.4%
7612%
-2%
1.4%
0 pointsfull points
Cycle position
12% of the score
71median 63
Today's operating margin of 20% is 0.95x its normal 22%: close to its usual level. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
2x
1.5x
1x
0.7x
0.9x
A trough earns points, a peak costs themfull points
10 years agonow 20%
Balance sheet
8% of the score
100median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDAMore cash than debt
100Interest coverOperating profit covers interest 151x
1001.5x
12x
151.2x
0 pointsfull points
Earnings quality
6% of the score
94median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Cash against profitOperating cash flow was 1.38x profit over 3 years
1000.7x
1x
1.3x
1.4x
0 pointsfull points
AccrualsCash ran ahead of profit by 6.6% of assets
938%
0%
-8%
-6.6%
0 pointsfull points
Beneish M-score-2.79
89-1.50
-1.78
-2.22
-3.00
-2.79
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Medical Instruments & Supplies
The closest names by size in the same industry